Two new studies suggest that the diabetes medication Ozempic may double the risk of a rare but serious condition that damages ...

The weight-loss market began feeling some growing pains as the year ended, creating more wariness for the upcoming year. For 2025, competition and supply constraints are areas to watch.

Given Wegovy’s success and record-high sales, a wave of investments has gone into the obesity space over the last couple of ...

The Nordic region accounts for about 1% of the world’s GDP and 0.3% of its population. Yet it has produced an impressive list ...

Biopharmaceutical firms engaged in developing weight-loss drugs were rewarded rather significantly in 2024. It’s what helped ...

In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their ...

Trump could keep Biden’s commitment to have Medicare pay for weight loss drugs such as Ozempic and Wegovy. But would ...

Eli Lilly seeks to defend its interests in a lawsuit challenging the FDA's decision on the supply status of its drugs ...

Anthony Anderson shares his mission to raise awareness about diabetes and cancer in a candid chat with Jazmyn Summers for EURweb.

Stocks splits have been a huge market theme in 2024, with big names across industries, from technology giant Nvidia to ...

Novo Nordisk’s UK unit has been suspended as a ... the PMCPA by a “concerned UK health professional” - contained an image of what appeared to be an overweight female and offered a free ...

From heart and kidney health to addiction reduction, GLP-1 drugs like Ozempic and Mounjaro may help with more than just ...